Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$1.75
-2.2%
$1.73
$0.71
$2.62
$276.05M1.01980,689 shs1.29 million shs
Cybin Inc. stock logo
HELP
Cybin
$5.54
+6.1%
$5.51
$4.29
$9.83
$269.52M0.81.66 million shs715,458 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.00
+9.3%
$4.70
$3.90
$15.00
$70.30M0.52214,839 shs814,778 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$6.23
-0.3%
$6.52
$1.30
$12.46
$274.01M-0.08189,040 shs87,908 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-0.56%+1.13%+3.47%-19.37%+75.49%
Cybin Inc. stock logo
HELP
Cybin
+1.36%+1.16%+1.95%-17.92%+521,999,900.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+1.10%+5.78%+29.18%-1.08%-53.40%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+2.97%-2.95%+18.37%+33.83%+265.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$1.75
-2.2%
$1.73
$0.71
$2.62
$276.05M1.01980,689 shs1.29 million shs
Cybin Inc. stock logo
HELP
Cybin
$5.54
+6.1%
$5.51
$4.29
$9.83
$269.52M0.81.66 million shs715,458 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$6.00
+9.3%
$4.70
$3.90
$15.00
$70.30M0.52214,839 shs814,778 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$6.23
-0.3%
$6.52
$1.30
$12.46
$274.01M-0.08189,040 shs87,908 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-0.56%+1.13%+3.47%-19.37%+75.49%
Cybin Inc. stock logo
HELP
Cybin
+1.36%+1.16%+1.95%-17.92%+521,999,900.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+1.10%+5.78%+29.18%-1.08%-53.40%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+2.97%-2.95%+18.37%+33.83%+265.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
2.67
Moderate Buy$7.00300.00% Upside
Cybin Inc. stock logo
HELP
Cybin
3.17
Buy$58.75960.47% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.50
Moderate Buy$5.00-16.67% Downside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$10.5068.54% Upside

Current Analyst Ratings Breakdown

Latest LFVN, HELP, CHRS, and NERV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
4/22/2026
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
UpgradeSell (D+)Hold (C-)
4/15/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Initiated CoverageMarket Outperform$14.00
4/13/2026
Cybin Inc. stock logo
HELP
Cybin
Initiated CoverageBuy
4/8/2026
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
Reiterated RatingSell (D+)
3/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
Reiterated RatingHold (C)
3/27/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Reiterated RatingSell (D-)
3/12/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Reiterated RatingNeutral$4.00 ➝ $7.00
3/2/2026
Cybin Inc. stock logo
HELP
Cybin
Boost Price TargetBuy$55.00 ➝ $95.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$42.17M6.40N/AN/A$0.50 per share3.50
Cybin Inc. stock logo
HELP
Cybin
N/AN/AN/AN/A$7.89 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.34$1.20 per share4.99$2.75 per share2.18
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($3.25) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$168.02M$1.461.20N/AN/A398.42%-860.29%-46.20%5/11/2026 (Estimated)
Cybin Inc. stock logo
HELP
Cybin
-$81.31M-$4.23N/AN/AN/AN/A-59.98%-50.80%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.6010.008.57N/A3.74%29.59%14.67%5/6/2026 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$26.80N/AN/AN/AN/AN/A-39.18%5/12/2026 (Estimated)

Latest LFVN, HELP, CHRS, and NERV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.13-$0.17-$0.04-$2.86N/AN/A
5/11/2026Q1 2026
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.2633N/AN/AN/A$14.34 millionN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
3/9/2026Q4 2025
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
-$0.31-$0.34-$0.03-$0.31$14.09 million$12.75 million
2/13/2026Q3 2026
Cybin Inc. stock logo
HELP
Cybin
-$0.53-$0.72-$0.19-$0.72N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
HELP
Cybin
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.183.00%N/A30.00%3 Years
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
0.61
1.47
1.45
Cybin Inc. stock logo
HELP
Cybin
N/A
13.78
13.78
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
2.03
1.03
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
36.29
36.29

Institutional Ownership

CompanyInstitutional Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
72.82%
Cybin Inc. stock logo
HELP
Cybin
17.94%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%

Insider Ownership

CompanyInsider Ownership
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
8.08%
Cybin Inc. stock logo
HELP
Cybin
15.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
330154.22 million141.76 millionOptionable
Cybin Inc. stock logo
HELP
Cybin
5051.63 million43.89 millionN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.81 million9.99 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
943.84 million39.28 millionNot Optionable

Recent News About These Companies

Minerva Announces Leadership Transition

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Coherus Oncology stock logo

Coherus Oncology NASDAQ:CHRS

$1.75 -0.04 (-2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$1.81 +0.06 (+3.43%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Cybin stock logo

Cybin NASDAQ:HELP

$5.54 +0.32 (+6.13%)
Closing price 04:00 PM Eastern
Extended Trading
$5.42 -0.12 (-2.09%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$6.00 +0.51 (+9.29%)
Closing price 04:00 PM Eastern
Extended Trading
$5.20 -0.80 (-13.25%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$6.23 -0.02 (-0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$6.26 +0.03 (+0.48%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.